SRPT Q4 2022 Earnings — Sarepta Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SRPTSarepta Therapeutics, Inc.

$2B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$258M+28.3% YoY

Gross Profit

$228M88.1% margin

Operating Income

-$107M-41.3% margin

Net Income

-$109M-42.3% margin

EPS (Diluted)

$-1.24

QoQ Revenue Growth

+12.2%

Cash Flow

Operating Cash Flow

-$92M

Free Cash Flow

-$100M

Stock-Based Comp.

$51M

Balance Sheet

Total Assets

$3.1B

Total Liabilities

$2.7B

Stockholders' Equity

$385M

Cash & Equivalents

$967M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$258M	$201M	+28.3%
Gross Profit	$228M	$170M	+34.1%
Operating Income	-$107M	-$106M	-1.0%
Net Income	-$109M	-$122M	+10.4%